Alivus Life Sciences
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Alivus Life Sciences is strategically transitioning towards a high-value API model, emphasizing its CDMO capabilities and advanced manufacturing technologies. Management's focus on operational efficiency and a robust pipeline of complex APIs is expected to drive revenue growth, with FY27 projected to deliver high single-digit growth and sustained margins above 30%. The company's strong cash position supports a significant capex plan, aimed at expanding its footprint in regulated markets. However, challenges such as raw material cost volatility and geopolitical uncertainties remain pertinent. Vista's financial outlook reflects stable revenue growth and improving margins, aligning with management's confidence in operational leverage and new product contributions. The industry backdrop is favorable, with Indian CDMOs poised to benefit from global supply chain shifts, although potential disruptions from raw material shortages warrant caution. Over the next 12-24 months, key opportunities include the successful commissioning of the Solapur facility and the expansion of the CDMO segment, while watchpoints include geopolitical risks and the complexities of scaling new capacities
Why We Like This Stock
- Management's pivot towards high-value APIs and CDMO services is expected to enhance margins and revenue growth
- A strong cash position allows for significant capital investments in capacity expansion and R&D, supporting long-term growth
- The favorable industry dynamics for Indian CDMOs present substantial opportunities for market share gains
Things To Watch Out For
- Raw material cost volatility and geopolitical uncertainties could impact margins and operational stability
- Customer concentration risks may pose challenges in maintaining revenue consistency
- The complexities of scaling new capacities could lead to temporary operational inefficiencies
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,283 | 2,387 | 2,552 | 2,553 | 2,744 |
| Profit Before Tax (Cr.) | 632 | 648 | 777 | 797 | 851 |
| PBT Margin | 27.7% | 27.1% | 30.4% | 31.2% | 31.0% |
| Net Profit (Cr.) | 480 | 488 | 586 | 601 | 642 |
| Earnings Per Share | 39.1 | 39.8 | 47.7 | 48.9 | 52.3 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Kotak Securities | ▲ Buy | 1,315 | 30-Jun-2026 |
Company Overview
Show Company Profile
Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. It offers various APIs, such as amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, solifenacin, atovaquone, etoricoxib, dapagliflozin, and sitagliptin for therapeutic areas, including cardiovascular, central nervous system, diabetes, oncology, urology, and pain management, as well as anti-fungal, anti-histaminic, anti-acne, anti-emetics immunomodulators, anti-ulceratives, immunosuppressant, respiratory agent, ophthalmologic agent, anti-spasmodic, and urology. The company also provides contract development and manufacturing comprising process development, analytical development and support, and API and intermediate manufacturing; and research and development, intellectual property, quality and compliance, customer experience, regulatory support. In addition, it exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited operates as a subsidiary of Nirma Limited.